CytomX Therapeutics (NASDAQ:CTMX) released its earnings results on Tuesday. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11), Fidelity Earnings reports. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. The business had revenue of $12.51 million for the quarter, compared to analyst estimates of $16.42 million.
Shares of CTMX stock traded up $3.20 on Wednesday, hitting $15.95. The stock had a trading volume of 1,315,395 shares, compared to its average volume of 402,168. CytomX Therapeutics has a twelve month low of $12.75 and a twelve month high of $35.00. The firm has a market capitalization of $674.91 million, a price-to-earnings ratio of -13.75 and a beta of 1.46.
Several equities analysts have recently issued reports on the stock. BidaskClub lowered shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 11th. HC Wainwright assumed coverage on shares of CytomX Therapeutics in a report on Thursday, September 13th. They issued a “buy” rating and a $32.00 price target for the company. Goldman Sachs Group assumed coverage on shares of CytomX Therapeutics in a report on Monday, October 15th. They issued a “neutral” rating and a $21.00 price target for the company. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday. Finally, Zacks Investment Research lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $34.88.
A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Great West Life Assurance Co. Can lifted its position in CytomX Therapeutics by 174.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 3,143 shares in the last quarter. SG Americas Securities LLC bought a new stake in CytomX Therapeutics in the 2nd quarter valued at $119,000. WINTON GROUP Ltd bought a new stake in CytomX Therapeutics in the 1st quarter valued at $205,000. Xact Kapitalforvaltning AB bought a new stake in CytomX Therapeutics in the 2nd quarter valued at $206,000. Finally, Fox Run Management L.L.C. bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $225,000. 71.53% of the stock is currently owned by institutional investors and hedge funds.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
See Also: Put Option
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.